Countdown to 2021 CBIIC：
Chairman and Chief Executive Officer of 3SBio Inc.
Mr. Lou Jing conducted post-doctoral research at the National Institutes of Health of the United States after obtaining a Ph.D. degree in molecular and cell biology from Fordham University in the United States in 1994. He also obtained an Executive Master of Business Administration from China Europe International Business School in 2008. In March 2013, Mr. Lou was selected as a member of the prestigious national program “the Recruitment Program of Global Experts”, which is also known as the “Thousand Talents Program”.
Dr. Lou has published in a number of academic journals on microbiology and medicinal biotechnology. His research has been recognized with various awards. 3SBio Inc. successfully developed the National Class II New Drugs--- injectable recombinant human erythropoietin (trade name: EPIAO) and the National ClassⅠNew Drug---recombinant human thrombopoietin (trade name: TPIAO) with the help of his leadership and organization. In addition, Dr. Lou has also undertaken various social positions. He was a high-level scientific and technical expert in Liaoning, a chief expert and vice president of Liaoning Biotechnology Association. Currently, he serves as Adjunct Professor of Shenyang Pharmaceutical University.